Spectral Medical Inc.

We're excited to share the positive results from the Tigris TRIAL of PMX hemoadsorption therapy for endotoxic septic shock (ESS): Results exceed the primary endpoint of 95% posterior probability of benefit for PMX on 28-day mortality. Read more: buff.ly/wP0GQ2a $EDT.TO

Spectral is proud to once again support the Unite for Sepsis Symposium hosted by Sepsis Alliance. 🗓 June 11–12, 2026 📍 Washington, D.C. More than a symposium—it’s a collaborative movement to advance sepsis care. Registration now open: UniteforSepsis.org #UniteForSepsis

Join us at the Bloom Burton & Co. Healthcare Investor Conference! Spectral CEO Chris Seto presents on Wednesday, April 22, at 10:30 AM ET. Our team is also available for 1-on-1 meetings throughout the day. Register: buff.ly/EtILn0Y #MedTech #Sepsis #Investing $EDT.TO

Save the Date: Endotoxemia & Sepsis in Zagreb Join these world-renowned experts for a deep dive into patient selection, trial implications, and the clinical reality of targeted endotoxin removal. May 8 | 14:40–15:40 👉 buff.ly/4oHrucK

TIGRIS Phase 3 results: “Publication in The Lancet Respiratory Medicine reflects the scientific rigor of the Tigris trial and the strength of the data supporting these findings,” said Dr. Matthieu Legrand, corresponding author of the Tigris manuscript..." buff.ly/Ch83dA2

CMO Dr. John Kellum joined Dilushi Wijayaratne for an interview at #WCN26. Dr. Kellum discusses the evolution of AKI care and why more work is needed to drive precision-based interventions for patients. Watch here: buff.ly/EI7i5RV #AKI #ISN

Spectral Medical is pleased to participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference. Chris Seto, CEO, will be speaking at 10:30 AM ET Wed. April 22. Management will also be meeting with investors throughout the day. Register: buff.ly/xR79XjX

Q4 and fiscal-year 2025 results are now available, alongside key clinical, regulatory, and commercial updates. buff.ly/f2IZ48o $EDT.TO

Now available: TIGRIS Phase 3 in Lancet Respiratory Medicine. In endotoxic septic shock (elevated endotoxin + organ dysfunction), polymyxin B haemoadsorption was associated with a high probability of reduced mortality at 28 & 90 days. 👉 buff.ly/nv4lO25 #ICU #FOAMed

Spectral Medical and Vantive announce publication of complete Phase 3 TIGRIS trial results in The Lancet Respiratory Medicine. • 95.3% (28d) & 99.4% (90d) probability of benefit • ARR: 10.3% & 15.5% • Safety comparable to standard care 👉 buff.ly/ZfCKTFY $EDT.TO

#SCCM2026 Late-breaking data shaping critical care—from subphenotypes to precision approaches in septic shock. Includes new findings on polymyxin B hemoadsorption in endotoxic septic shock. 🗓 Mar 24 | 9:45–10:45 AM CT 📍 Skyline Ballroom, W375D buff.ly/xLYDOZO

Ahead of #SCCM2026: An independent meta-analysis suggests earlier PMX-HP (3–12h) may be associated with lower mortality, improved oxygenation, and faster organ recovery in septic shock. buff.ly/OEQo9F7 #SepticShock #CriticalCare

New publication: Integration of polymyxin B hemoadsorption into a CRRT circuit for pediatric endotoxin-mediated septic shock. A case report describing technical feasibility and practical considerations in the ICU. buff.ly/q1emb6q #pediatricsepsis #endotoxin #ICU

Now available: SCCM Podcast on Endotoxin Activity and Precision Medicine in Septic Shock. Host Marilyn Bulloch, PharmD, BCPS, FCCM, and Dr. John Kellum discuss endotoxin activity, organ failure, and mortality in septic shock. 🎧 Listen: buff.ly/GbL24Ju #Sepsis #SCCM

TIGRIS Trial/Premarket Approval Update: We expect to submit our Premarket Approval application for PMX-20R to the U.S. FDA in late April–mid May 2026, reflecting inclusion of complete 12-month mortality data from the TIGRIS Trial. buff.ly/iSMEnzl

Now available to replay: CCCF 2025 Keynote: TIGRIS – A Clinical Trial for Septic Shock with Endotoxemia. Dr. Matthieu Legrand and Dr. John Kellum discuss trial design, endotoxemia, and precision approaches in septic shock. 👉 buff.ly/xbLfye4 #Sepsis #CriticalCare

Sepsis is biologically heterogeneous and endotoxin activity is not uniform across patients. A Critical Care review of 54 sepsis studies examines how the Endotoxin Activity Assay (EAA™) has been used for risk stratification and targeted intervention. buff.ly/E3MV8AQ

Endotoxic septic shock (EAA ≥0.60 with severe organ dysfunction) affected ~23% of patients and was associated with >3.5× higher mortality. Not all septic shock is the same—biology matters. 👉 buff.ly/orkvwct #CriticalCare #FOAMed #ClinicalStudies

Recognizing those who have survived sepsis and the long-term impact that can follow critical illness. Learn how you can support sepsis awareness and survivor education at the Sepsis Alliance: buff.ly/bmQuLqD #SepsisSurvivorWeek

The EAA™ was developed to identify when endotoxin is a meaningful driver of risk in septic shock. Clinical studies showed higher endotoxin activity is linked to increased mortality, supporting biology-driven patient characterization in the ICU. 👉 buff.ly/mM87hpy

Septic shock is biologically heterogeneous. Two patients may look the same clinically, yet differ in endotoxin activity and host immune response. Measuring functional endotoxin activity helps reveal what’s actually driving disease biology in sepsis. buff.ly/x8Kssyz